Internal Medicine, Infectious Disease · Oklahoma City, OK
NPI
1871729517
Since 2009
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
1111 N Lee Ave Ste 249
Oklahoma City, OK, 73103
Phone (405) 594-5848
Groups this clinician bills Medicare through
Medicare paid, 2024
$193K
24,375 services
Medicare patients, 2024
725
Average age 71
Drug cost, 2024
$334K
932 prescriptions
Company payments, 2025
$3,336
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ahmad Ashfaq was code 99232 (hospital e&m - subsequent), 1,696 times for 524 patients. In total Ahmad Ashfaq billed 24,375 services in 26 codes, and Medicare paid $193K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-01-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,696 | 524 | $58.64 | $99K |
| 99233 Hospital E&M - Subsequent | Facility | 394 | 217 | $88.54 | $35K |
| 99223 Hospital E&M - Initial | Facility | 319 | 299 | $128.91 | $41K |
| 99214 Office E&M - Established | Office | 74 | 47 | $87.87 | $6,502 |
| 99204 Office E&M - New | Office | 27 | 26 | $116.95 | $3,158 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 19 | 17 | $11.74 | $223 |
By year: 2022 $244K for 3,354 services; 2023 $243K for 3,325 services; 2024 $193K for 24,375 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ahmad Ashfaq prescribed most often to Medicare patients was Daptomycin, with 137 prescriptions and refills. In total Ahmad Ashfaq wrote 932 Medicare prescriptions that cost $334K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Daptomycin Generic | 137 | 137 | 31 | $78K |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | 115 | 115 | 36 | $23K |
| Ertapenem Ertapenem Sodium | 89 | 89 | 23 | $32K |
| Ceftriaxone Ceftriaxone Sodium | 88 | 88 | 25 | $13K |
| Meropenem Generic | 65 | 65 | 15 | $9,229 |
| Cefazolin Sodium Generic | 31 | 31 | Under 11 | $1,377 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 31 | 41 | 18 | $613 |
| Doxycycline Hyclate Generic | 30 | 54 | 21 | $672 |
| Ceftazidime Generic | 29 | 29 | Under 11 | $4,383 |
| Cefadroxil Generic | 28 | 74 | 19 | $831 |
| Ampicillin-Sulbactam Ampicillin Sod/Sulbactam Sod | 15 | 15 | Under 11 | $2,629 |
| Azithromycin Generic | 14 | 23 | Under 11 | $126 |
| Imipenem-Cilastatin Sodium Imipenem/Cilastatin Sodium | 14 | 14 | Under 11 | $10K |
| Nafcillin Sodium Generic | 14 | 14 | Under 11 | $8,116 |
| Cefepime Hcl Generic | 14 | 14 | Under 11 | $1,586 |
Brand drugs: 45 claims; generic drugs: 887 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ahmad Ashfaq $3,336 ($3,336 in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbvie Inc. with $2,700.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 2 | $2,700 |
| Paratek Pharmaceuticals, Inc. | 6 | $160 |
| Pfizer Inc. PFE | 6 | $117 |
| La Jolla Pharmaceutical Company | 2 | $113 |
| Insmed, Inc. INSM | 4 | $96.74 |
| Merck Sharp & Dohme LLC MRK | 2 | $41.76 |
| Aimmune Therapeutics, Inc. | 1 | $24.14 |
| Gilead Sciences, Inc. GILD | 1 | $23.25 |
| Shionogi Inc 4507.T | 1 | $20.56 |
| Cumberland Pharmaceuticals, Inc. CPIX | 1 | $20.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.